Skip Navigation


Annals of Oncology Advance Access originally published online on October 27, 2006
Annals of Oncology 2007 18(1):136-142; doi:10.1093/annonc/mdl348
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/1/136    most recent
mdl348v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nickenig, C
Right arrow Articles by Hiddemann, W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nickenig, C
Right arrow Articles by Hiddemann, W
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

hematologic malignancies

Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas—results of a randomized comparison by the German Low-Grade Lymphoma Study Group

C Nickenig1, M Dreyling1, E Hoster1,2, W-D Ludwig3, B Dörken4, M Freund5, C Huber6, A Ganser7, L Trümper8, R Forstpointner1, M Unterhalt1 and W Hiddemann1,*

1 Department of Internal Medicine III, Ludwig-Maximilians University, Munich Grosshadern
2 Institute of Medical Informatics, Biometry and Epidemiology, University of Munich
3 Department of Hematology and Oncology, Charité Campus Berlin-Buch
4 Department of Hematology and Oncology, Charité Berlin Campus Virchow-Klinikum
5 Division of Hematology and Oncology, University Rostock
6 Department of Internal Medicine III, University of Mainz
7 Department of Hematology, Hemostasis and Oncology, Hannover Medical School
8 Department of Hematology and Oncology, Georg-August University, Göttingen, Germany

* Correspondence to: Dr W. Hiddemann, Department of Internal Medicine III, Ludwig-Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany. Tel: +49-89-7095-2550; Fax: +49-89-7095-5550; E-mail: Wolfgang.Hiddemann{at}med.uni-muenchen.de

Myeloablative radio-chemotherapy with subsequent autologous stem cell transplantation (ASCT) significantly prolongs progression free and probably overall survival in follicular lymphoma (FL) in first remission. The current trial explored prospectively the rate of successful stem cell mobilization in patients with advanced stage FL after initial therapy with either Mitoxantrone, Chlorambucil, Prednisone (MCP) or Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) as part of a prospective randomized comparison of both regimens. ASCT patients received Dexa-BEAM (Dexamethasone, BCNU, Melphalan, Etoposide, Cytarabine) for mobilization of stem cells. Stem cells were collected and a minimum of 2 x 2.0 x 106/kg bw CD34+ was required for ASCT.

Of 79 evaluable patients, 58 (73%) had follicular lymphoma, 13 (16%) mantle cell lymphoma and 8 (10%) lymphoplasmacytic lymphoma.

In the 45 patients assigned to CHOP, stem cell collection was successful in 42 cases (93%, 95% CI 82% to 99%). This high mobilization rate after CHOP could be confirmed in 61 subsequent patients (87%). In contrast, after MCP therapy stem cell collection was successful in only 15 of 34 patients (44%, 95% CI 27% to 62%; P = 0.0003).

In conclusion, initial therapy with MCP significantly impairs the ability to collect stem cells and should be avoided for first line therapy of younger patients potentially qualifying for high dose consolidation and ASCT in first remission.

Key words: chemotherapy, indolent lymphoma, stem cell collection


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.